Metagenomi Therapeutics, Inc.
MGXMetagenomi Therapeutics is a preclinical-stage biotechnology company focused on developing curative genetic medicines through a proprietary metagenomics-based discovery engine.
Earnings
Next report
Nov 10, 2026 (in 2 months)Competitors
By market cap
Profile
Metagenomi Therapeutics is a preclinical-stage biotechnology company focused on developing curative genetic medicines through a proprietary metagenomics-based discovery engine. The company leverages machine learning and artificial intelligence to identify novel gene editing tools from natural environments, aiming to overcome the limitations of traditional CRISPR/Cas9 systems. Their core value proposition lies in a vast database of signature editing systems capable of precise gene knockdown, deletion, and large-gene insertion for a variety of genetic diseases.
Metagenomi positions itself as a next-generation genome editing company with a significantly larger toolbox of nucleases and integration systems than first-generation CRISPR companies.
FAQ
- What is Metagenomi Therapeutics, Inc.'s market cap?
- Metagenomi Therapeutics, Inc. (MGX) has a market capitalization of $43.4M and trades on NASDAQ.
- Who are Metagenomi Therapeutics, Inc.'s competitors?
- Metagenomi Therapeutics, Inc.'s key competitors include Editas Medicine, Inc., CRISPR Therapeutics AG, Precision BioSciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does Metagenomi Therapeutics, Inc. partner with?
- Metagenomi Therapeutics, Inc.'s notable partners include Ionis Pharmaceuticals, Inc., Acuitas Therapeutics, Inc., ModernaTx, Inc., and others.
- Where is Metagenomi Therapeutics, Inc. headquartered?
- Metagenomi Therapeutics, Inc. is headquartered in United States of America and employs approximately 236 people. It has been publicly traded since 2024.